AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31769793
Drug: GSK2838232 (≥50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (≥50 mg) with cobicistat 150 mg
Trial: 31770437
Drug: BST-236 (aspacytarabine)
RxNorm normalized name: Aspacytarabine
DrugBank: Aspacytarabine (DB17226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BST-236 (aspacytarabine) administered intravenously once daily over 60 minutes for 6 consecutive days at doses ranging from 0.3 to 6 g/m2 per day.
Trial: 31770616
Drug: Genotype CC
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype CC of rs1333049
Trial: 31771630
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota composition in AS patients with increased fecal calprotectin (≥ 200 mg/kg, n=36)
Trial: 31771630
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota composition in AS patients with normal fecal calprotectin (≤ 50 mg/kg, n=57)
Trial: 31772121
Drug: First-line HER2-targeted
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy
Trial: 31772517
Drug: Medication Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Therapy (MT)
Trial: 31772517
Drug: Medication Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Therapy (MT) (after PSM)
Trial: 31772605
Drug: Perioperative continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative continuation of statin therapy (CS group)
Trial: 31772605
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy (DS group)
Trial: 31772766
Drug: Subretinal injection
RxNorm normalized name: LUXTURNA Suspension for Subretinal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal injection of ranibizumab after vitrectomy with ILM peeling
Trial: 31772984
Drug: Local hyperthermia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local hyperthermia at 39°C to 43°C delivered using radiofrequency waves at 100 Mhz once a week after proton therapy.
Trial: 31772984
Drug: Proton irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton irradiation at a dose of 70 to 72 Gy delivered at 2.0 Gy per fraction daily for 7 weeks.
Trial: 31772984
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of local hyperthermia and proton irradiation.
Trial: 31773439
Drug: Bevacizumab and
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and weekly paclitaxel therapy
Trial: 31774125
Drug: Fasting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting insulin and HOMA-IR
Trial: 31774522
Drug: Gemcitabine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1200 mg/m2, later amended to 1000 mg/m2 on days 1 and 8 every 3 weeks), plus trastuzumab (8-mg/kg loading dose, then 6 mg/kg), and pertuzumab (840-mg loading dose, then 420 mg) once every 3 weeks.
Trial: 31774957
Drug: Low C-PTP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low C-PTP and d-dimer <1000 ng/mL
Trial: 31774957
Drug: Moderate C-PTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate C-PTP and d-dimer <500 ng/mL
Trial: 31774957
Drug: d-dimer level
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-dimer level 500 to 999 ng/mL
Trial: 31774957
Drug: No diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diagnosis of pulmonary embolism and no anticoagulant therapy
Trial: 31774957
Drug: Diagnostic strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic strategy with low C-PTP and d-dimer <1000 ng/mL
Trial: 31774957
Drug: Alternative strategy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative strategy with low C-PTP and d-dimer <500 ng/mL
Trial: 31775667
Drug: Grade 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 3 to 5 chemotherapy-related toxicities
Trial: 31775677
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg) followed by misoprostol (400 μg, two doses 4 hrs apart)
Trial: 31775677
Drug: Misoprostol alone
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol alone (400 μg, two doses 4 hrs apart)
Trial: 31776631
Drug: Chemokine receptor-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemokine receptor-4 targeted PET/CT
Trial: 31776899
Drug: INC280 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INC280 (300 mg twice daily) + buparlisib (80 mg once daily)
Trial: 31776899
Drug: INC280 (monotherapy)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INC280 (monotherapy)
Trial: 31778074
Drug: Crizotinib (ALK,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (ALK, MET & ROS1 inhibitor)
Trial: 31778267
Drug: Capmatinib 600
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 600 mg bid capsules
Trial: 31778267
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg bid tablets
Trial: 31778267
Drug: Capmatinib 200
RxNorm normalized name: capmatinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capmatinib 200 mg bid, 250 mg bid, and 450 mg bid capsules
Trial: 31778267
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg bid tablets/600 mg bid capsules
Trial: 31778281
Drug: Pain EASE
RxNorm normalized name: Pain Ease Mist
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain EASE program (internet-delivered self-management program based on cognitive behavioral therapy)
Trial: 31778798
Drug: Ceritinib (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceritinib (750 mg/day, fasted)
Trial: 31780140
Drug: Medication-related adverse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-related adverse events (MRE) in anaesthesia care
Trial: 31780140
Drug: Vasoconstrictor agents,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoconstrictor agents, benzodiazepines, and neuromuscular blocking agents
Trial: 31780255
Drug: Atezolizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (15 mg/kg for patients <18 years, 1200 mg for patients 18-29 years)
Trial: 31783773
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol serum levels ≥ 20 mg/L
Trial: 31783773
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol serum levels > 40 mg/L
Trial: 31783773
Drug: Anti-drug antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-drug antibodies detected in serum samples
Trial: 31783816
Drug: Precision radiotherapy
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision radiotherapy (volumetric modulated arc therapy or stereotactic body radiotherapy) with 18 × 2.33Gy in 3.5 weeks
Trial: 31785337
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (RT) to at-risk areas in the involved neck (60-66 Gy) and uninvolved neck (54 Gy)
Trial: 31785503
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (monotherapy or combination therapy)
Trial: 31785831
Drug: Intrathecal autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs) - 100 million cells infused after a standard lumbar puncture at the L3-4 level, administered 11 months after injury.
Trial: 31786124
Drug: Chemoradiotherapy (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy)
Trial: 31786124
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost)
Trial: 31786276
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost technique (60 Gy high dose and 54 Gy low dose in 30 fractions)
Trial: 31786971
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for ASCVD
Trial: 31787498
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) glibenclamide (BIIB093; glyburide) treatment
Trial: 31789931
Drug: Allergen-specific immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-specific immune signature-guided dietary elimination therapy
Trial: 31790766
Drug: Sofosbuvir-based direct-acting
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir-based direct-acting antivirals (DAAs)
Trial: 31790766
Drug: Sofosbuvir-free direct-acting
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir-free direct-acting antivirals (DAAs)
Trial: 31792136
Drug: Antibody blockade
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody blockade of IL12p40
Trial: 31793850
Drug: FDG PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG PET/MRI with dedicated liver and rectal MRI
Trial: 31793891
Drug: PAGETEX medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals (Metvixia incubation for 30 minutes and 635 nm red light illumination for 2 hours and 30 minutes, total fluence of 12 J/cm²)
Trial: 31793891
Drug: PAGETEX medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals
Trial: 31794031
Drug: Support for
RxNorm normalized name: GNP Diabetic Support Formula Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support for HIV infection and substance use treatment
Trial: 31794605
Drug: Gender-affirming treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-affirming treatment in transgender men (TM)
Trial: 31794605
Drug: Gender-affirming treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-affirming treatment in transgender women (TW)
Trial: 31795981
Drug: Mass Testing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Testing, Treatment and Tracking (MTTT)
Trial: 31796469
Drug: MK-3475 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 (200 mg every 21 days) in combination with BCG
Trial: 31796939
Drug: Preoperative chemical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemical vestibular ablation with 0.5 - 1.0 mL of 40 mg/mL nonbuffered gentamicin administered in three intratympanic instillations.
Trial: 31796939
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative gentamicin treatment).
Trial: 31796953
Drug: High-fructose diet
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose diet (150 g daily) for 8 weeks
Trial: 31797105
Drug: IgM-enriched immunoglobulins
RxNorm normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched immunoglobulins (Pentaglobin) 250 mg/kg (5 mL/kg) per day for 72 hours
Trial: 31798447
Drug: Ayahuasca (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (one dose)
Trial: 31798754
Drug: Protein-enriched milk
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-enriched milk (2 × 20 g protein/day)
Trial: 31799207
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sorafenib and hepatic arterial infusion chemotherapy
Trial: 31799498
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors (infliximab, etanercept, adalimumab, MTX)
Trial: 31801624
Drug: Utomilumab 1.2-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utomilumab 1.2-5 mg/kg or 100 mg flat dose every 4 weeks plus mogamulizumab 1 mg/kg (weekly in Cycle 1 followed by biweekly in Cycles ≥2)
Trial: 31801624
Drug: Utomilumab/mogamulizumab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utomilumab/mogamulizumab combination
Trial: 31801732
Drug: Tremelimumab monotherapy
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab monotherapy (750 mg via intravenous infusion every 4 weeks for seven cycles, then every 12 weeks for two additional cycles)
Trial: 31804299
Drug: Higher Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Sequential Organ Failure Assessment score
Trial: 31804669
Drug: Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide single-tablet regimen
Trial: 31806397
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum betaine <77.7 μmol/L
Trial: 31806397
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum betaine ≥77.7 μmol/L
Trial: 31806613
Drug: Metoprolol optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol optimal dosing pathway
Trial: 31807036
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) treatment starting from the second trimester (24-27 weeks)
Trial: 31807036
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) treatment starting from the third trimester (28-30 weeks)
Trial: 31809725
Drug: Recombinant E1E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant E1E2 complex vaccine
Trial: 31810978
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cholinesterase inhibitor and memantine
Trial: 31813938
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) 55-75 mg/m
Trial: 31814209
Drug: One-session virtual
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session virtual reality exposure treatment (VRET)
Trial: 31814753
Drug: Oliceridine IV
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine IV (G-protein selective agonist at the µ-opioid receptor)
Trial: 31817795
Drug: 4G8-SDIE (Fc-optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4G8-SDIE (Fc-optimized FLT3 antibody)
Trial: 31817885
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of extracts of restharrow root, Java tea, and goldenrod herb (Aqualibra)
Trial: 31819193
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro assays with metformin
Trial: 31819674
Drug: Intravenous amisulpride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amisulpride, 10 mg dose
Trial: 31820038
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity (Matsuda Insulin Sensitivity Index; IS)
Trial: 31820038
Drug: Insulin production
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin production
Trial: 31820038
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in glucose metabolism
Trial: 31820199
Drug: Pemetrexed/Erlotinib (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed/Erlotinib (pemetrexed 500 mg/m2)
Trial: 31820981
Drug: Covalent inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covalent inhibitor of KRAS (specific dosage and duration not mentioned)
Trial: 31821172
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg d6-α-tocopherol
Trial: 31821172
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg d6-α-tocopherol
Trial: 31821456
Drug: Vedolizumab IV
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV 75 mg
Trial: 31821456
Drug: Vedolizumab IV
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV 300 mg
Trial: 31821530
Drug: High oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oral splint
Trial: 31822542
Drug: Standardised diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised diagnostic and treatment algorithm involving neurologists and cardiologists; transesophageal echocardiogram for patients depending on age strata; implantable cardiac monitor for all patients; PFO closure planned for patients <60 years with PFO and no AF evidence within 6 months after stroke.
Trial: 31823806
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) 60 mg once per month for three consecutive months
Trial: 31823832
Drug: Vorinostat, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat, starting dose 180 mg/m², intra-patient dose escalation until maximum tolerated dose (MTD)
Trial: 31824412
Drug: Intravenous Thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Thrombolysis
Trial: 31826340
Drug: Asciminib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib (10 to 200 mg, administered once or twice daily)
Trial: 31827803
Drug: Antibiotics administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics administration
Trial: 31827803
Drug: Adrenergic agent
RxNorm normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic agent administration
Trial: 31828307
Drug: Increased sex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased sex chromosome dosage
Trial: 31828337
Drug: Aztreonam/avibactam loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam/avibactam loading dose of 500/137 mg (30 min infusion), followed by maintenance doses of 1500/410 mg (3 h infusions) q6h (Cohort 1)
Trial: 31828337
Drug: Aztreonam/avibactam loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam/avibactam loading dose of 500/167 mg (30 min infusion), followed by maintenance doses of 1500/500 mg (3 h infusions) q6h (Cohorts 2+3)
Trial: 31828337
Drug: IV metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV metronidazole 500 mg q8h (all patients)
Trial: 31828337
Drug: Aztreonam/avibactam treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam/avibactam treatment
Trial: 31829203
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) at a starting dose of 50 Gy in 5 fractions every other day (biologically effective dose: 100 Gy)